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Aim: This study aimed to investigate the safety of insulin degludec (degludec) in rela-
tion to age and risk of hypoglycaemia post hoc in individuals with type 2 diabetes
(T2D) (SWITCH 2 trial).
Methods: In this crossover study, individuals with T2D who were at risk of
hypoglycaemia were randomized to double-blind treatment with degludec or insulin
glargine 100 units/mL (glargine U100) ± oral antidiabetic drugs. After 32 weeks,
patients crossed over to the other treatment. Primary endpoint was number of over-
all severe (positively adjudicated) or glucose-confirmed (plasma glucose <56 mg/dL;
3.1 mmol/L) symptomatic hypoglycaemia events during the two 16-week mainte-
nance periods.
Results: For individuals ≤65 (n = 450) and >65 (n = 270) years, baseline median
(range) duration of diabetes was 12 (1–40) vs 15 (1–54) years, mean HbA1c was
7.7% vs 7.4% and mean estimated glomerular filtration rate was 87.0 vs
63.7 mL/min/1.73 m2, respectively. No significant differences in HbA1c reduction
were seen in individuals ≤65 or >65 years. During both maintenance periods, treat-
ment with degludec lowered rates of hypoglycaemia (overall/nocturnal symptomatic)
vs those with glargine U100 in individuals ≤65 (31% vs 43%) and >65 (30% vs 41%)
years. With degludec and glargine U100, respectively, six vs nine severe hyp-
oglycaemic events occurred in individuals ≤65 years and four vs eight events
occurred in those >65 years. Adverse event rates were 3.2 and 3.3 events/patient-
year for individuals ≤65 years and were 3.5 and 4.1 events/patient-year for individ-
uals >65 years with degludec and glargine U100, respectively.
Conclusion: Treatment with degludec was safe and effective, with a frequency of
hypoglycaemia lower than that with glargine U100 in both younger and older individ-
uals (>65 years) with T2D.
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1 | INTRODUCTION
Type 2 diabetes (T2D) is a chronic, progressive disease that frequently
necessitates treatment with basal insulin to maintain adequate
glycaemic control.1,2 In an ageing population with increasing longevity,
the global burden of diabetes in individuals 65 years of age or older is
projected to increase from 122.8 million in 2017 to 253.4 million in
2045.3
Hypoglycaemia, primarily associated with diabetes therapies, par-
ticularly insulin, is common in T2D,4,5 and increases with age and lon-
ger duration of diabetes.6 Non-severe episodes are associated with
increased utilization of healthcare services and loss of work time,7–9
as well as impairment of quality of life; prevention of these episodes
is therefore important. Severe hypoglycaemia is of even greater con-
cern, as it has been shown to be associated with increased risk of car-
diovascular events and mortality.10,11 As with non-severe events,
severe episodes can increase utilization of healthcare resources, with
adverse economic consequences.12
Delay in intensifying treatment with insulin for many individuals
with T2D is common, with fear of hypoglycaemia among patients and
healthcare providers an important contributing factor.13 The problem
of clinical inertia may be magnified in the context of older individ-
uals.14 Treatment delay could place older individuals at greater risk of
the microvascular and macrovascular complications of diabetes, as
they often have less organ reserve and more comorbid conditions
than younger individuals.15
Basal insulin analogues, now in widespread use, have advantages
over human insulin in reducing the risk of hypoglycaemia because of
better pharmacokinetic/pharmacodynamic (PK/PD) profiles.16 The
basal insulin analogue insulin degludec (degludec) has a PK/PD profile
with an ultra-long duration of action,17 and these PK/PD properties
have been shown to be preserved in elderly individuals.18 In type 1 dia-
betes, degludec has a four-times lower PD variability than insulin
glargine 100 units/mL (glargine U100) (AUC GIR0-24h,SS, coefficient of
variation, 20% vs 82%).19 The performance of degludec vs glargine
U100 has been studied in a large clinical development programme in
which degludec was associated with a lower rate of hypoglycaemia,
with rate reductions of 17%–86%, compared with glargine U100.20 In a
dedicated cardiovascular outcomes trial (DEVOTE), a statistically signifi-
cant 40% lower rate of adjudicated severe hypoglycaemia was
observed in individuals using degludec compared with those using
glargine U100.21
Most randomized trials of insulins include very few older individ-
uals, a population that is heterogeneous with respect to prevalence
and severity of comorbidity, frailty and overall health.22 Consequently,
little information exists concerning the performance of basal insulin
analogues in older individuals with diabetes, particularly with respect
to hypoglycaemia. A pre-planned meta-analysis of seven trials com-
paring degludec and glargine U100 in older patients (≥65 years) indi-
cated that degludec had a 24% lower rate of overall confirmed
hypoglycaemia vs glargine U100, and a 36% lower rate of confirmed
nocturnal hypoglycaemia.23 Secondary analysis of the DEVOTE trial,
which compared degludec with glargine U100, showed that degludec
was associated with a lower rate of hypoglycaemia than glargine
U100, regardless of age.24 A post hoc analysis of data from the
SWITCH 2 trial25 has been utilized in the present report to explore
whether older (>65 years) individuals with T2D responded similarly to
younger individuals, with respect to the definitions of hypoglycaemia
used in the primary analysis and other safety parameters when com-
paring degludec with glargine U100.
2 | METHODS
The detailed design of the SWITCH 2 trial and results of the primary
analysis have been published.19 Briefly, SWITCH 2 was a randomized,
double-blind, treat-to-target, two-period crossover trial in which
adults (≥18 years) with T2D currently undergoing treatment with
basal insulin, with or without oral antidiabetic drugs, were randomized
1:1 to receive degludec (Novo Nordisk, Bagsværd, Denmark) once
daily and glargine U100 (Sanofi, Paris, France) once daily, in a random-
ized sequence by period. Participants were also randomized 1:1 within
each sequence to a morning dose, between awakening and breakfast,
or an evening dose, between the main meal and bedtime. To maintain
blinding, both insulins were administered using vial and syringe
(100 U/mL, 10 mL vials). Each treatment sequence included a
16-week titration period and a 16-week maintenance period. Primary
endpoint was the number of overall symptomatic hypoglycaemia
(severe or blood glucose-confirmed [<56 mg/dL {3.1 mmol/L}]) events
during the maintenance period.19 Other endpoints included the rate
of nocturnal symptomatic hypoglycaemia events, severe or blood
glucose-confirmed between 12:01 AM and 05:59 AM (both inclusive)
and severe hypoglycaemia, also assessed during the maintenance
period. An external, blinded committee positively adjudicated all
severe events.
To reflect a broad population of individuals with T2D at risk for
hypoglycaemia, inclusion criteria required that individuals must fulfil
at least one of the following criteria: at least one severe episode based
on American Diabetes Association criteria;14 a moderate degree of
chronic renal failure (estimated glomerular filtration rate [eGFR]
30–59 mL/min/1.73 m);2 reduced awareness of hypoglycaemia; insu-
lin use for more than five years; or experience of a hypoglycaemic
event (symptoms and/or blood glucose ≤70 mg/dL [<3.9 mmol/L])
within the previous 12 weeks.
In this post hoc analysis, data from the primary trial25 were exam-
ined according to age category at baseline; the younger group com-
prised individuals 65 years of age or younger and the older group
comprised individuals above 65 years of age. Statistical analysis was
similar to that used in the primary trial. Briefly, a Poisson model with
individuals as random effect, with treatment, period, sequence and
dosing time as fixed effects, and with logarithm of the observation
time as offset was used to estimate the rate ratio for each classifica-
tion of hypoglycaemia during the maintenance period.25 Age group
was added to the model as a fixed class variable to facilitate age com-
parisons pooled across treatments.
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3 | RESULTS
3.1 | Participants
Among the original cohort, 450 (62.5%) participants were 65 years of
age or younger and 270 (37.5%) were above 65 years of age (Table 1).
Among younger participants, the distribution according to sex was
similar (49.8% female); however, among older participants, there were
fewer females than males (42.2% vs 57.8%). At baseline, younger par-
ticipants tended to be heavier (mean body mass index, 32.8 [5.8] vs
31.2 [5.3] kg/m2), to have higher mean HbA1c (7.7% [1.1] vs 7.4%
[1.0] {60.3 [12.2] vs 57.9 [11.2] mmol/mol}), to have higher mean
fasting plasma glucose (FPG) (7.8 [2.9] vs 7.2 [2.9] mmol/L) and to
have a greater prevalence of current smokers (20.0% vs 7.8%). How-
ever, younger participants had a shorter median [range] duration of
diabetes (12 [1–40] vs 15 [1–54] years) and better renal function
(mean eGFR 87.0 [18.9] vs 63.7 [16.8] mL/min/1.73 m2) compared
with older participants. A much smaller proportion of younger partici-
pants had moderate chronic renal failure (10.9% vs 40.7% of younger
and older participants, respectively). With respect to any age-related
differences in inclusion criteria relevant to the risk of hypoglycaemia,
a larger proportion of older participants had been treated with insulin
for more than 5 years (52.6% vs 47.6% of older and younger partici-
pants, respectively). However, fewer older participants had experi-
enced at least one severe hypoglycaemia event during the previous
year (14.4% vs 17.6% of older and younger participants, respectively).
Completion rates were comparable for both younger and older partici-
pants, and comparable for both treatments, ranging from 89% to 91%.
3.2 | Comparisons between age groups in the pooled
population
The cumulative number of hypoglycaemic events, by age group, dur-
ing the two 16-week maintenance periods is shown in Figure 1. No
statistically significant difference in older vs younger participants was
observed in the estimated risk of overall symptomatic hypoglycaemia
(relative risk [RR], 1.05 [95% CI, 0.79; 1.40]; P = 0.73) or nocturnal
symptomatic hypoglycaemia (RR, 0.93 [95% CI, 0.63; 1.36]; P = 0.70).
Older participants tended to experience more severe hypoglycaemic
events, although the difference was not statistically significant (RR,
1.38 [95% CI, 0.60; 3.17]; P = 0.45).
Mean basal insulin dose was statistically significantly higher for youn-
ger than for older participants throughout the trial (age contrast, older vs
younger, −0.14 U/kg [95% CI, −0.21; −0.08]; P < 0.001 [period 1]
and −0.21 U/kg [95% CI: −0.29; −0.12]; P < 0.0001 [period 2])
(Figure S1).
With respect to glycaemic control, both younger and older partici-
pants showed reductions from baseline in mean HbA1c; no statisti-
cally significant difference was found in change from baseline HbA1c
between older and younger participants in treatment period 1 (age
contrast, older vs younger, −0.01% [95% CI, −0.15; 0.13]; P = 0.91) or
in treatment period 2, −0.05% [95% CI: −0.18; 0.08]; P = 0.45).
Mean fasting plasma glucose was also reduced from baseline in
both age groups. However, the magnitude of decrement was greater
for older compared with younger participants during both treatment
periods (age contrast, older vs younger, period 1, −0.51 mmol/L
[95% CI, −0.87; –0.15]; P = 0.0054; period 2, −0.56 mmol/L [95% CI,
−1.02; −0.10]; P = 0.0168).
3.3 | Comparisons by treatment within age group
The observed rate of severe or blood glucose (BG)-confirmed symp-
tomatic hypoglycaemia was lower for degludec compared with
glargine U100 in older as well as in younger participants during the
maintenance period (younger group, 184 vs 263 events/100 patient-
years of exposure [PYE] for degludec and glargine U100, respectively;
older group, 188 vs 269 events/100 PYE for degludec and glargine
U100, respectively) (Table 2), with an estimated 31% and 30% lower
rates of severe or BG-confirmed symptomatic hypoglycaemic events
with degludec compared with glargine U100, in the younger group
(treatment ratio, degludec:glargine U100, 0.69 [95% CI, 0.58; 0.83];
P < 0.0001) and in the older group (treatment ratio, degludec:glargine
U100, 0.70 [95% CI, 0.56; 0.88]; P = 0.0023), respectively (Figure 2).
Treatment with degludec was also associated with an estimated 43%
and 41% lower rates of nocturnal symptomatic hypoglycaemia than
rates with glargine U100, in the younger group (treatment ratio,
degludec:glargine U100, 0.57 [95% CI, 0.42; 0.78]; P = 0.0005) and in
the older group (treatment ratio, degludec:glargine U100, 0.59
[95% CI, 0.39; 0.89]; P = 0.0117), respectively (Figure 2). The number
of severe events was low in both the younger group (six with
degludec and nine with glargine U100) and the older group (four with
degludec and eight with glargine U100), and the risk of severe
hypoglycaemia was not statistically significantly different for either
younger (treatment ratio, degludec:glargine U100, 0.52 [95% CI, 0.15;
1.89]; P = 0.32) or older (treatment ratio, degludec:glargine U100,
0.63 [95% CI: 0.13; 2.98]; P = 0.56) participants by treatment.
HbA1c decreased with both treatments during the first 16-week
titration period, after which values plateaued (Figure S2). No statisti-
cally significant difference was seen between treatments in either age
group (degludec–glargine U100, 0.16% [95% CI, −0.02; 0.35];
P = 0.07 and − 0.05% [95% CI, −0.26; 0.15]; P = 0.60) for younger
and older participants, respectively. FPG decreased from baseline dur-
ing the first 32-week treatment period for both treatments, after
which FPG remained relatively stable across both treatments
(Figure S3).
3.4 | Adverse events
Over the entire trial, in the safety analysis set, 307 of 444 (69.2%)
younger patients and 194 of 269 (72.2%) older patients reported
adverse events (AEs). The percentage of younger patients reporting
AEs was almost identical for degludec and glargine U100 (57.5% and
57.8%, respectively). However, for older patients, a smaller proportion
reported AEs with degludec (56.9% vs 66.7% for degludec vs glargine
U100, respectively).
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Serious AEs by preferred term and system organ class occurring
≥5% in either treatment arm for both age groups are listed in Table S1.
These were mostly upper respiratory in nature. There were seven fatal
events in total: two in patients treated with degludec (none in the youn-
ger group; one associated with sudden cardiovascular death and one
caused by stroke in the older group) and five in patients treated with
glargine U100 (one secondary to acute myocardial infarction and one
caused by sepsis in the younger group; two associated with malignancy
and one caused by sepsis in the older group).
4 | DISCUSSION
Results of the randomized, double-blind, crossover trial, SWITCH 2, were
examined to assess the effect of age on hypoglycaemia risk, comparing
degludec with glargine U100. The SWITCH 2 trial was powered to eval-
uate the superiority of degludec vs glargine U100 with respect to overall
symptomatic hypoglycaemia. During the maintenance period, treatment
with degludec was associated with statistically significantly lower rates
TABLE 1 Baseline characteristics, by age group
Characteristic ≤65 years (n = 450) >65 years (n = 270)
Age (years) median [range] 56.6 [20.9;65.0] 71.5 [65.1;89.2]
Sex (n, %)
Female 224 (49.8) 114 (42.2)
Male 226 (50.2) 156 (57.8)
Ethnicity (n, %)
Hispanic or Latino 175 (38.9) 87 (32.2)
Not Hispanic or Latino 275 (61.1) 183 (67.8)
Ethnicity
White 356 (79.1) 222 (82.2)
Black or African American 65 (14.4) 41 (15.2)
Native Hawaiian or other Pacific islander 1 (0.2) 0 (0)
American Indian or Alaska native 4 (0.9) 3 (1.1)
Asian 19 (4.2) 3 (1.1)
Other 5 (1.1) 1 (0.4)
Body weight (kg) 93.8 (20.3) 88.3 (17.6)
BMI (kg/m2) 32.8 (5.8) 31.2 (5.3)
Duration of diabetes (years), median [range] 12 [1–40] 15 [1–54]
Exposure to insulin >5 years (n, %) 214 (47.6) 142 (52.6)
Experience of at least one severe hypoglycaemic event during the previous yeara (n, %) 79 (17.6) 39 (14.4)
Impaired awareness of hypoglycaemia b (n, %) 81 (18.0) 48 (17.8)
Experience of at least one hypoglycaemic eventc within 12 weeks prior to visit 1 (screening) (n, %) 298 (66.2) 180 (66.7)
eGFR (mL/min/1.73 m2) 87.0 (18.9) 63.7 (16.8)
Moderate chronic renal failured (n, %) 49 (10.9) 110 (40.7)
Smoking status (n, %)
Never smoked 230 (51.1) 134 (49.6)
Previous smoker 130 (28.9) 115 (42.6)
Current smoker 90 (20.0) 21 (7.8)
HbA1c (%) 7.7 (1.1) 7.4 (1.0)
HbA1c (mmol/mol) 60.3 (12.2) 57.9 (11.2)
FPG (mmol/L) 7.8 (2.9) 7.2 (2.9)
FPG (mg/dL) 140.9 (52.9) 130.6 (51.4)
Note. All values are mean (SD) unless otherwise specified.
Abbreviations: BMI, body mass index; CKD-EPI, chronic kidney disease epidemiology collaboration; eGFR, estimated glomerular filtration rate; FPG, fasting
plasma glucose; n, number of subjects; SD, standard deviation.
aEvent requiring assistance of another person to actively administer carbohydrate or glucagon, or to take other corrective action. Plasma glucose
concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient
evidence.
bHistory of impaired autonomic responses (tremulousness, sweating, palpitations and hunger) during hypoglycaemia.
cDefined by symptoms of hypoglycaemia and/or event with low glucose measurement (≤70 mg/dL [≤3.9 mmol/L]).
dGlomerular filtration rate 30–59 mL/min/1.73 m2 per CKD-EPI by central laboratory analysis.
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of severe and symptomatic hypoglycaemic events (BG-confirmed) com-
pared with glargine U100, with a 31% reduction in younger patients
(≤65 years) and a 30% reduction in older patients (>65 years). Con-
cerning nocturnal symptomatic hypoglycaemia, the reduction in rates
were 43% and 41%, respectively, for these age groups. These treatment
differences were comparable between age groups, and this lower rate
was similar to the 27% lower rate of overall confirmed hypoglycaemia
(estimated rate ratio, degludec:glargine U100, 0.73 [95% CI, 0.56; 0.96])
and the 39% lower rate in nocturnal hypoglycaemia (estimated rate ratio,
degludec:glargine U100, 0.61 [95% CI, 0.37; 1.03]) during the mainte-
nance period reported in a pre-planned meta-analysis of seven phase IIIa
open-label trials in individuals aged at least 65 years of age, comparing
degludec and glargine U100 in T2D.24 In contrast to the SWITCH 2 trial,
the core trials in the meta-analysis were powered to detect differences
in HbA1c. Nevertheless, these similarly lower rates across trials with
heterogeneous patient populations, ranging from insulin-naïve to basal-
bolus users, with or without an increased risk of hypoglycaemia at base-
line, support the overall benefit of treatment with degludec compared
with glargine U100.
The number of severe hypoglycaemic events reported in the pre-
sent analysis were not statistically different by treatment for either
age group, probably because the overall number of events was very
low. As this was a treat-to-target trial, as expected, no treatment dif-
ferences were observed in change in HbA1c from baseline in either
the older or the younger participants. Younger individuals required a
higher mean insulin dose (U/kg) compared with older individuals
throughout the trial, which may have been related to greater insulin
resistance, in line with the tendency of a higher body mass index
among younger individuals.
Older individuals with T2D are generally at increased risk of, and
more vulnerable to, hypoglycaemia than younger individuals, for sev-
eral reasons, including impaired renal function,26 reduced ability to
recognize and respond to hypoglycaemia,27 and altered physiological
responses to low glucose levels.28 Symptoms of hypoglycaemia
become less intense and their symptom profile changes with increas-
ing age,29 with symptomatic responses manifesting only at BG levels
lower than those in younger individuals, leaving less time to recognize
and respond to them.30,31 Thus, when hypoglycaemia develops in an
older individual with T2D, it might not be identified or reported, which
may explain the absence of a significantly higher rate of overall
hypoglycaemia in older individuals, as was observed in the present
study.
Reduced awareness of hypoglycaemia with advancing age may
increase the risk that an event progresses in severity and results in
more severe events in the older age group. There was a numerically
greater rate of severe hypoglycaemia in older individuals compared
with younger individuals (RR, 1.38) in the current trial, although the
trend was not statistically significant. Severe hypoglycaemia is gener-
ally much more common in real-world populations than in randomized
clinical trials.4,5,32 In addition, continuous glucose monitoring has dem-
onstrated that many episodes are unrecognized and under-reported.33
Furthermore, it has been estimated that only 5% of self-reported
severe hypoglycaemia events among individuals with diabetes who
are underging pharmacological treatment are captured by traditional
healthcare utilization-based surveillance systems, suggesting a sub-
stantial underestimate of the true burden.34 This may be related, at
least in part, to the low number of episodes of severe hypoglycaemia
in both age groups (15 events in 11/413 younger individuals and
12 events in 11/240 older individuals) (Table 2). Baseline characteris-
tics that could have influenced the risk of hypoglycaemia were not
markedly different between younger and older individuals, with the
F IGURE 1 Cumulative number of hypoglycaemic events, for
younger (≤65 years) and older (>65 years) individuals
Abbreviations: BG, blood glucose; CI, confidence interval; NS, not
significant; RR, risk ratio for older: younger individuals.
Full analysis set. Values are from the two 16-week maintenance periods
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exception of an almost four-fold greater prevalence of chronic moder-
ate renal failure in older individuals (40.7% vs 10.9%) (Table 1).
Multiple comorbidities, polypharmacy and increased use of con-
comitant medications in older individuals with T2D may increase the
risk of hypoglycaemia, and insulin metabolism may alter with age.35 In
particular, a greater prevalence and severity of renal insufficiency in
older individuals and a greater frequency of visual and/or cognitive
impairment may interfere with routine self-care in individuals with
diabetes.22,36,37 Frailty37 can compound the burden of self-
management in older individuals and increase hypoglycaemia risk. Liv-
ing alone may also increase vulnerability, as external assistance to
treat severe hypoglycaemia is difficult or impossible to engage. It may
also contribute, in part, to failure to identify hypoglycaemic events,
and may lead to an underestimation of severe events in older individ-
uals with T2D. The morbidity associated with hypoglycaemia may be
more common and severe in older individuals. This includes a greater
risk of falls and injuries such as fractures, which occur more frequently
with advancing age.36
An important limitation of the present study is that the analysis of
data from patients subdivided into age groups was not prespecified
and was thus post hoc. Furthermore, information that would allow
formal examination of the level of frailty in older individuals was not
TABLE 2 Summary of hypoglycaemic events for younger (≤65 years) and older (>65 years) individuals, by treatment group
≤65 years (n = 413) Insulin degludec Insulin glargine U100 Total
Type of hypoglycaemia N % E R N % E R N % E R
Severe or BG-confirmed symptomatic 85 21.4 220 184 118 30.3 310 263 156 37.8 530 223
Nocturnal severe or BG-confirmed symptomatic 39 9.8 64 53.6 61 15.7 109 92.57 81 19.6 173 72.95
Severe 6 1.5 6 5.02 8 2.1 9 7.64 11 2.7 15 6.33
>65 years (n = 240) Insulin degludec Insulin glargine U100 Total
Type of hypoglycaemia N % E R N % E R N % E R
Severe or BG-confirmed symptomatic 57 24.4 133 188 77 33.6 186 269 100 41.7 319 228
Nocturnal severe or BG-confirmed symptomatic 22 9.4 41 58 30 13.1 66 95.42 44 18.3 107 76.45
Severe 4 1.7 4 5.65 7 3.1 8 11.57 11 4.6 12 8.57
Note. Values during the two 16-week maintenance periods.
Abbreviations: %, percentage of participants; BG, blood glucose; E, number of events; N, number of participants; R, rate (number of events divided by
patient-years of exposure multiplied by 100).
F IGURE 2 Hypoglycaemic events for younger (≤65 years) and older (>65 years) individuals, by treatment group
Abbreviations: BG, blood glucose; CI, confidence interval.
Values are treatment ratios (insulin degludec/insulin glargine U100) for the two 16-week maintenance periods.
P-values derived using a Poisson model with logarithm of exposure time (100 years) as offset; estimates adjusted for treatment period, period
sequence and dosing time as fixed effects, and subjects as a random effect
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collected. It would have been valuable to assess whether frail patients
were at higher risk of the differing severities of hypoglycaemia. In this
study, a larger percentage (57.8%) of individuals in the older age group
were male; this may affect the generalizability of results to the older
adult population, which tends to have a greater proportion of females.
Significant strengths of the SWITCH 2 trial25 include the double-
blinded, treat-to-target design. A crossover design allowed partici-
pants to serve as their own controls when comparing treatment
efficacy. In terms of assessing safety, the studies were powered with
hypoglycaemia as the primary endpoint, as opposed to HbA1c, which
was used in other trials that were being conducted for regulatory pur-
poses. Furthermore, severe as well as BG-confirmed symptomatic
hypoglycaemia events were included, and all severe episodes were
confirmed by adjudication. Notwithstanding the high proportion of
older males in the trial, both the inclusion criteria for hypoglycaemia
risk and the inclusion of older individuals in this study provide valu-
able insight into a population seen in real-world practice.
To conclude, in patients with T2D, older and younger patients
were at similar risk of overall symptomatic hypoglycaemia or noctur-
nal symptomatic hypoglycaemia, but older patients showed a ten-
dency toward higher risk of severe hypoglycaemia. Treatment with
degludec led to similar reductions in HbA1c and a similar adverse-
event profile, with a lower risk of hypoglycaemia than treatment with
glargine U100, both in older and younger individuals with T2D.
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